LITZMAN, Jiří, Jindřich LOKAJ, Marcela KREJČÍ, Sáva PEŠÁK and Gareth MORGAN. Isoprinosine does not protect against frequent respiratory tract infections in childhood. Eur. J. Pediatr. Berlin: Springer-Verlag, 1999, vol. 158, No 1, p. 32-37. ISSN 0340-6199.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Isoprinosine does not protect against frequent respiratory tract infections in childhood
Authors LITZMAN, Jiří (203 Czech Republic, guarantor), Jindřich LOKAJ (203 Czech Republic), Marcela KREJČÍ, Sáva PEŠÁK (203 Czech Republic) and Gareth MORGAN.
Edition Eur. J. Pediatr, Berlin, Springer-Verlag, 1999, 0340-6199.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30209 Paediatrics
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.280
RIV identification code RIV/00216224:14110/99:00001564
Organization unit Faculty of Medicine
UT WoS 000077651800007
Keywords in English Immunotherapy; Inosine pranobex; lymphocyte subsets; respiratory tract infections
Tags Immunotherapy, Inosine pranobex, lymphocyte subsets, respiratory tract infections
Changed by Changed by: prof. MUDr. Jiří Litzman, CSc., učo 403. Changed: 18/6/2009 11:43.
Abstract
Isoprinosine, an in vitro immuno-enhancing agent principally acting by stimulating T-lymphocytes, is one of a number of agents sometimes used in an attempt to prevent recurrent respiratory infections in children, although there are no formal trials for this particular drug. We performed a placebo-controlled double-blind trial to assess the efficacy of isoprinosine (50 mg/kg per day) for 6 weeks followed by 50 mg/kg per day twice weekly for 6 weeks in the prevention of frequent acute respiratory tract infections in 102 children aged 4-8 years. A total of 43 children treated with isoprinosine and 41 with placebo finished the study. Despite a transient increase in the total number of CD3+, CD4+ and CD8+ T-lymphocytes after 6 weeks of daily isoprinosine treatment, there was no difference in the number and length of duration of acute respiratory infections, number of antibiotic courses and number of days with cough, pharyngitis, rhinitis and increased body temperature (> or = 37.0 degrees C and > or = 38.0 degrees C). There were no changes in markers of T- or B-lymphocyte activation (CD25, HLA-DR, CD45RA/RO, CD23). CONCLUSION: Attempts at immunomodulation using isoprinosine in the dose and for the duration used may increase the total numbers of both CD4 and CD8 T-lymphocytes but is ineffective in prevention of respiratory tract infections in childhood.
Abstract (in Czech)
Isoprinosin je neúčinný u dětí s častými respiračními infekcemi.
Links
IZ2169, research and development projectName: Imunomodulace v léčbě dětí s častými infekcemi.
Investor: Ministry of Health of the CR, Immunomodulation in the treatment of children with frequent respiratory infections
PrintDisplayed: 13/7/2024 13:28